Bernstein Harold, Maze Therapeutics’ President, R&D & CMO, sold 9,705 shares at $26.22 each on Sep. 4, leaving 0 shares owned. For investors, the transaction records a completed insider sale and shows that Harold no longer held Maze Therapeutics stock after the reported transaction.
Key Highlights
- Bernstein Harold held 0 Maze Therapeutics shares after the transaction.
- The sale occurred on 4 September 2026 under transaction code S.
- Harold serves as Maze Therapeutics’ President, R&D & CMO.
Maze Therapeutics, Inc. (NASDAQ: MAZE) President, R&D & CMO Bernstein Harold sold 9,705 shares, reducing his reported ownership to 0 shares. The transaction was completed at $26.22 per share on 4 September 2026.
Transaction Code S Marks Open-Market Sale
The trade involved 9,705 shares at $26.22 per share. The transaction date was 4 September 2026. Maze Therapeutics’ reported ownership for Harold stood at 0 shares after the sale.
FAQs
Q: What happened in the Maze Therapeutics insider sale?
A: Bernstein Harold sold 9,705 Maze Therapeutics shares at $26.22 per share on 4 September 2026. His reported ownership after the transaction was 0 shares.
Q: What was the impact of the MAZE stock transaction?
A: The transaction changed Bernstein Harold’s reported Maze Therapeutics holdings to 0 shares. It involved 9,705 shares and was completed at $26.22 per share.
Q: Who sold Maze Therapeutics shares?
A: Bernstein Harold, Maze Therapeutics’ President, R&D & CMO, completed the sale. The transaction used code S and occurred on 4 September 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.